Developer docs
API playgroundTry for free, no card

Search company profiles

Elevation Oncology

Full company profile

uuid0000vde

Namestring
Elevation Oncology
Legal namestring
Elevation Oncology
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Elevation Oncology was a clinical-stage precision oncology biopharmaceutical company founded in 2019 and headquartered in New York. The company was built around developing targeted antibody-drug conjugate (ADC) therapies for patients with genomically defined solid tumors. Its core asset, EO-3021, was in-licensed from CSPC Megalith Biopharmaceutical (CSPC Pharmaceutical Group) in July 2022, granting Elevation Oncology exclusive development and commercialization rights in all territories outside of China, Hong Kong, Taiwan, and Macau. The company positioned itself around a horizontal segmentation approach, targeting any solid tumor indication where the ADC's biology could address a defined genomic alteration.

The business operated on a one-time license / development-oriented revenue model. Elevation Oncology was pre-revenue throughout its operating history; no commercialization infrastructure, no product pricing, and no customer base were disclosed. The company funded operations through a $32.5M Series A2 (July 2020), a $65M Series A2 extension (November 2020), a $50M senior secured loan facility from K2 HealthVentures (July 2022; $30M initial tranche plus a $20M option), and a $50M public offering of stock, warrants, and pre-funded warrants (June 2023), implying roughly $197M of cumulative capital raised. Cumulative EBITDA losses across 2020-2024 ran into the high-tens of millions per year (~$44.7M in 2024, ~$40.3M in 2023, ~$94.5M in 2022 inclusive of what appears to be a non-recurring impairment or in-licensing charge), reflecting heavy clinical-stage R&D burn without offsetting product revenue.

The company was acquired by Concentra Biosciences under a definitive merger agreement announced June 9, 2025, at $0.36 per share plus a contingent value right, with closing subject to majority stockholder tender and a minimum cash condition of $26.4 million. Leadership included Joseph Ferra as CEO, Shawn Leland as founder/advisor, and Timothy Clackson as a director. Following closing, Elevation Oncology was expected to operate as a subsidiary of Concentra Biosciences and to cease independent operations.

Short descriptiontext

Elevation Oncology was a pre-revenue, clinical-stage biopharmaceutical company developing EO-3021, an antibody-drug conjugate for genomically defined solid tumors. Founded in 2019, it licensed EO-3021 from CSPC and was acquired by Concentra Biosciences in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision oncology, antibody drug conjugates, biopharmaceutical development, genomic cancer therapy, oncology drug pipeline
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Precision Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biopharmaceutical company. The company generates no current revenue and is focused on developing its ADC pipeline, particularly EO-3021, through clinical development toward potential regulatory approval and commercialization. In 2025, the company entered into a merger agreement for acquisition by Concentra Biosciences.

prnewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Elevation Oncology is a clinical-stage biopharmaceutical company that discovers and develops precision antibody drug conjugates (ADCs) targeted at genomically defined solid tumors. Its lead asset is EO-3021, an ADC in-licensed from CSPC Pharmaceutical Group and being advanced through clinical development. The company's pipeline focuses on biomarker-driven oncology therapeutics rather than broad chemotherapy approaches.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Elevation Oncology is a biopharmaceutical company focused on developing targeted cancer treatments. The company's core product is EO-3021, an antibody drug conjugate (ADC) in clinical development for genomically defined solid tumors. The company operates with a precision oncology approach, developing treatments that target specific genetic alterations in cancer cells.

Product and service1 record
1EO-3021
CategoryPrecision Oncology Therapeutics / Antibody Drug Conjugates
Description

EO-3021 is an antibody drug conjugate (ADC) being developed by Elevation Oncology for the treatment of genomically defined solid tumors. It was in-licensed from CSPC Pharmaceutical Group and represents the company's lead clinical asset.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-09
Description

Elevation Oncology entered into a merger agreement to be acquired by Concentra Biosciences for $0.36 per share plus a contingent value right. The transaction was expected to close in July 2025, subject to stockholder tender and minimum cash conditions.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-07-27
Description

License agreement granting Elevation Oncology exclusive rights to develop and commercialize products containing EO-3021 outside of China, Hong Kong, Taiwan, and Macau. This partnership enabled the company to expand its clinical pipeline with a novel antibody drug conjugate candidate.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large Japanese pharmaceutical company that pioneered Enhertu, a leading ADC for solid tumors, in partnership with AstraZeneca. Represents the dominant incumbent in the ADC space against which smaller ADC developers compete.

TypeEmerging player
Description

Clinical-stage company developing next-generation ADCs for solid tumors, including FRα, HER2, and other targeted programs. Comparable ADC pipeline focus and oncology indication overlap.

3Mythic Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing ADCs designed to address challenges of solid tumor penetration. Comparable as a focused ADC developer targeting solid tumors with next-generation technology.

TypeDirect peer
Description

Clinical-stage oncology company that historically pursued antibody-drug conjugates alongside other targeted cancer therapeutics. Comparable as a small-cap ADC and antibody-based oncology developer.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and ADC candidates for solid tumors. Comparable as a platform-based targeted oncology developer with antibody engineering capabilities.

TypeDirect peer
Description

Clinical-stage biopharma developing a pipeline of ADCs and ADC platforms (e.g., Dolaflexin, Dolasynthen) for cancer. Closely comparable as an ADC-focused company with platform technology and genomically defined oncology programs.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), an ADC-adjacent modality for solid tumors. Comparable as a small-cap ADC-adjacent targeted oncology developer.

TypeDirect peer
Description

Clinical and commercial-stage biopharma focused exclusively on antibody drug conjugates for solid tumors and hematologic malignancies. Directly comparable as an ADC-pure-play competitor pursuing similar targeted oncology indications.

TypeEmerging player
Description

European clinical-stage biotech developing next-generation ADCs with proprietary linker and payload chemistry for solid tumors. Comparable as a focused ADC platform player targeting solid tumor indications.

TypeBroad incumbent
Description

Following the Seagen acquisition, Pfizer owns a leading ADC platform with approved assets such as Adcetris and Padcev. Represents a broad incumbent competing across multiple ADC targets and solid tumor indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elevation Oncology

Precision Oncology Therapeuticselevationoncology.com

Elevation Oncology was a pre-revenue, clinical-stage biopharmaceutical company developing EO-3021, an antibody-drug conjugate for genomically defined solid tumors. Founded in 2019, it licensed EO-3021 from CSPC and was acquired by Concentra Biosciences in 2025.

What Elevation Oncology does

Elevation Oncology was a clinical-stage precision oncology biopharmaceutical company founded in 2019 and headquartered in New York. The company was built around developing targeted antibody-drug conjugate (ADC) therapies for patients with genomically defined solid tumors. Its core asset, EO-3021, was in-licensed from CSPC Megalith Biopharmaceutical (CSPC Pharmaceutical Group) in July 2022, granting Elevation Oncology exclusive development and commercialization rights in all territories outside of China, Hong Kong, Taiwan, and Macau. The company positioned itself around a horizontal segmentation approach, targeting any solid tumor indication where the ADC's biology could address a defined genomic alteration.

The business operated on a one-time license / development-oriented revenue model. Elevation Oncology was pre-revenue throughout its operating history; no commercialization infrastructure, no product pricing, and no customer base were disclosed. The company funded operations through a $32.5M Series A2 (July 2020), a $65M Series A2 extension (November 2020), a $50M senior secured loan facility from K2 HealthVentures (July 2022; $30M initial tranche plus a $20M option), and a $50M public offering of stock, warrants, and pre-funded warrants (June 2023), implying roughly $197M of cumulative capital raised. Cumulative EBITDA losses across 2020-2024 ran into the high-tens of millions per year (~$44.7M in 2024, ~$40.3M in 2023, ~$94.5M in 2022 inclusive of what appears to be a non-recurring impairment or in-licensing charge), reflecting heavy clinical-stage R&D burn without offsetting product revenue.

The company was acquired by Concentra Biosciences under a definitive merger agreement announced June 9, 2025, at $0.36 per share plus a contingent value right, with closing subject to majority stockholder tender and a minimum cash condition of $26.4 million. Leadership included Joseph Ferra as CEO, Shawn Leland as founder/advisor, and Timothy Clackson as a director. Following closing, Elevation Oncology was expected to operate as a subsidiary of Concentra Biosciences and to cease independent operations.

Elevation Oncology firmographics

Firmographics
Name
Elevation Oncology
Legal name
Elevation Oncology
Website
https://elevationoncology.com
Company type
Public
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
Elevation Oncology was a pre-revenue, clinical-stage biopharmaceutical company developing EO-3021, an antibody-drug conjugate for genomically defined solid tumors. Founded in 2019, it licensed EO-3021 from CSPC and was acquired by Concentra Biosciences in 2025.
Ownership category
akta.pro rank

Elevation Oncology industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Precision oncology
  • Antibody drug conjugates
  • Biopharmaceutical development
  • Genomic cancer therapy
  • Oncology drug pipeline

Where Elevation Oncology is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Elevation Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical stage biopharmaceutical company. The company generates no current revenue and is focused on developing its ADC pipeline, particularly EO-3021, through clinical development toward potential regulatory approval and commercialization. In 2025, the company entered into a merger agreement for acquisition by Concentra Biosciences.

Go-to-market motion1 record

Marketing channels1 record

Elevation Oncology product offering

Product offering

Core offering

Elevation Oncology is a clinical-stage biopharmaceutical company that discovers and develops precision antibody drug conjugates (ADCs) targeted at genomically defined solid tumors. Its lead asset is EO-3021, an ADC in-licensed from CSPC Pharmaceutical Group and being advanced through clinical development. The company's pipeline focuses on biomarker-driven oncology therapeutics rather than broad chemotherapy approaches.

Product overview

Elevation Oncology is a biopharmaceutical company focused on developing targeted cancer treatments. The company's core product is EO-3021, an antibody drug conjugate (ADC) in clinical development for genomically defined solid tumors. The company operates with a precision oncology approach, developing treatments that target specific genetic alterations in cancer cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • EO-3021 EO-3021 is an antibody drug conjugate (ADC) being developed by Elevation Oncology for the treatment of genomically defined solid tumors. It was in-licensed from CSPC Pharmaceutical Group and represents the company's lead clinical asset.

Companies that use Elevation Oncology

Customer profile

Segments1 record

Ideal customer profiles2 records

Elevation Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Elevation Oncology partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Concentra BiosciencescoreStrategic or Co-development Partner · 9 June 2025Elevation Oncology entered into a merger agreement to be acquired by Concentra Biosciences for $0.36 per share plus a contingent value right. The transaction was expected to close in July 2025, subject to stockholder tender and minimum cash conditions.
  • CSPC Megalith Biopharmaceutical (CSPC Pharmaceutical Group)coreOEM/ Whitelabel/ Licensing Partner · 27 July 2022License agreement granting Elevation Oncology exclusive rights to develop and commercialize products containing EO-3021 outside of China, Hong Kong, Taiwan, and Macau. This partnership enabled the company to expand its clinical pipeline with a novel antibody drug conjugate candidate.

Scale indicators3 records

Recent moves7 records

Expansion highlights3 records

Elevation Oncology competitors and assessment

Company assessment

Broad incumbents

  • Daiichi Sankyo: Large Japanese pharmaceutical company that pioneered Enhertu, a leading ADC for solid tumors, in partnership with AstraZeneca. Represents the dominant incumbent in the ADC space against which smaller ADC developers compete.
  • Pfizer (Seagen): Following the Seagen acquisition, Pfizer owns a leading ADC platform with approved assets such as Adcetris and Padcev. Represents a broad incumbent competing across multiple ADC targets and solid tumor indications.

Emerging players

  • ProfoundBio: Clinical-stage company developing next-generation ADCs for solid tumors, including FRα, HER2, and other targeted programs. Comparable ADC pipeline focus and oncology indication overlap.
  • Mythic Therapeutics: Clinical-stage biotech developing ADCs designed to address challenges of solid tumor penetration. Comparable as a focused ADC developer targeting solid tumors with next-generation technology.
  • Tubulis: European clinical-stage biotech developing next-generation ADCs with proprietary linker and payload chemistry for solid tumors. Comparable as a focused ADC platform player targeting solid tumor indications.

Direct peers

  • Pyxis Oncology: Clinical-stage oncology company that historically pursued antibody-drug conjugates alongside other targeted cancer therapeutics. Comparable as a small-cap ADC and antibody-based oncology developer.
  • Zymeworks: Clinical-stage biotech developing bispecific antibodies and ADC candidates for solid tumors. Comparable as a platform-based targeted oncology developer with antibody engineering capabilities.
  • Mersana Therapeutics: Clinical-stage biopharma developing a pipeline of ADCs and ADC platforms (e.g., Dolaflexin, Dolasynthen) for cancer. Closely comparable as an ADC-focused company with platform technology and genomically defined oncology programs.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), an ADC-adjacent modality for solid tumors. Comparable as a small-cap ADC-adjacent targeted oncology developer.
  • ADC Therapeutics: Clinical and commercial-stage biopharma focused exclusively on antibody drug conjugates for solid tumors and hematologic malignancies. Directly comparable as an ADC-pure-play competitor pursuing similar targeted oncology indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Elevation Oncology social profiles

Digital presence

Elevation Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elevation Oncology leadership team

Management profile

Number of profiles

Profiles3 records

Elevation Oncology funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elevation Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elevation Oncology

What does Elevation Oncology do?

Elevation Oncology is a clinical-stage biopharmaceutical company that discovers and develops precision antibody drug conjugates (ADCs) targeted at genomically defined solid tumors. Its lead asset is EO-3021, an ADC in-licensed from CSPC Pharmaceutical Group and being advanced through clinical development. The company's pipeline focuses on biomarker-driven oncology therapeutics rather than broad chemotherapy approaches.

Is Elevation Oncology a public or private company?

Elevation Oncology is a public company. It is classified as public and is currently acquired.

When was Elevation Oncology founded?

Elevation Oncology was founded in 2019. It employs 1 to 10 people.

Where is Elevation Oncology based?

Elevation Oncology is headquartered in Boston, United States, in the North America region.

How does Elevation Oncology make money?

One revenue line is on record: drug Development and Commercialization.

Who are Elevation Oncology's main competitors?

Broad incumbents on record are Daiichi Sankyo and Pfizer (Seagen). Emerging players are ProfoundBio, Mythic Therapeutics and Tubulis. Direct peers are Pyxis Oncology, Zymeworks, Mersana Therapeutics, Bolt Biotherapeutics and ADC Therapeutics.

Does Elevation Oncology have an API?

No public API is recorded for Elevation Oncology.

What industry is Elevation Oncology in?

Elevation Oncology's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestThe High-Stakes Gamble: CVRs in Distressed Biotech M&A and What Investors Need to KnowConcentra Biosciences acquires distressed biotechs like Elevation Oncology and Kronos Bio using contingent value rights (CVRs), paying minimal cash and deferring payouts to future asset sales. The strategy minimizes upfront costs but carries risks from litigation and market volatility, making CVRs a high-risk, high-reward instrument for investors.YahooConcentra to acquire Elevation in bid to eliminate another biotech ‘zombie’Elevation Oncology agreed to be acquired by Concentra Biosciences, a vehicle controlled by Tang Capital Partners, at $0.36 per share. The deal includes contingent value rights tied to the company's sole drug, EO-1022, and is expected to close in July pending shareholder approval.PR NewswireElevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value RightElevation Oncology entered a definitive merger agreement with Concentra Biosciences to be acquired for $0.36 in cash per share plus a contingent value right. The CVR gives Elevation 100% of closing net cash over $26.4 million and 80% of proceeds from EO-1022 dispositions within five years. The tender offer is set to commence June 23, 2025, with closing expected in July 2025.BenzingaElevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% - (ELEV)Elevation Oncology discontinued the development of EO-3021, a Claudin 18.2 antibody-drug conjugate for advanced gastric and gastroesophageal junction cancers, after Phase 1 trial data showing a 22.2% objective response rate failed to meet the company's internal threshold for success.PR NewswireElevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming MilestonesElevation Oncology announced it has initiated dosing in a Phase 1 clinical trial evaluating its Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab for patients with advanced gastric/GEJ cancer, with initial combination data expected in Q4 2025 or Q1 2026. The company also reported it expects to share additional monotherapy data from the dose escalation and expansion study in H1 2025, building on prior data showing a 42.8% confirmed ORR. For its second program, the HER3 ADC EO-1022, preclinical data is anticipated in H1 2025 and an IND filing is planned for 2026.BenzingaElevation Oncology: Promising Cancer Therapies Earn Analyst Praise - ASTELLAS PHARMA INC by Astellas PharWilliam Blair initiated coverage on Elevation Oncology, Inc. with an Outperform rating, citing a favorable risk-to-reward ratio at the company's current valuation driven by its antibody-drug conjugate pipeline targeting Claudin 18.2 and HER3. The analyst highlighted that Astellas Pharma's recent approval of Vyloy, a CLDN18.2-targeted therapy, reduces clinical and regulatory risks for Elevation's lead program EO-3021, which has shown promising early Phase I data with 32 patients treated and generally well-tolerated safety. The estimated total addressable market for CLDN18.2-positive gastric and GEJ cancer is projected at $6.6 billion across five major regions, with Elevation nominating EO-1022 as its HER3 ADC development candidate targeting an IND filing in 2026.Business InsiderBuy Rating Affirmed for Elevation Oncology Amid Promising EO-3021 Phase 1 Results and Strategic Development ApproachH.C. Wainwright analyst Swayampakula Ramakanth affirmed a Buy rating on Elevation Oncology with a $6.00 price target, citing promising Phase 1 data for EO-3021 in Claudin 18.2-expressing gastric cancers. The therapy showed a meaningful response rate and favorable safety profile. JMP Securities also reiterated a Buy with a $7.00 target.BenzingaWhy Is Penny Stock Elevation Oncology Trading Lower On Tuesday?Elevation Oncology Inc. reported initial Phase 1 trial data for EO-3021 showing a 42.8% objective response rate in patients with Claudin 18.2 expression in ≥20% of tumor cells but 0% response in those with lower expression levels. The company's stock fell 59% on Tuesday as investors reacted to the biomarker-dependent efficacy results, which highlight the importance of patient selection for the drug's potential success. Elevation Oncology plans to proceed with dose expansion studies and expects to share additional data in the first half of 2025, with its $110.8 million cash position sufficient to fund operations into 2026.BenzingaDow Jumps Over 300 Points; US Trade Gap Narrows In June - (ELEV), Jumia Technologies (NYSE:JMIA)U.S. stock indices rallied on Tuesday, with the Dow Jones gaining over 300 points and the S&P 500 rising 1.06%, as the U.S. trade deficit narrowed to $73.1 billion in June from $75 billion in May, though still slightly above analyst expectations of $72.5 billion. Notable individual stock movements included VBI Vaccines surging 178% and Lumen Technologies gaining 57% after announcing $5 billion in new business contracts. Conversely, Elevation Oncology shares dropped 60% following second-quarter results, and Jumia Technologies fell 46% after reporting worse-than-expected quarterly sales.PR NewswireElevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsElevation Oncology announced promising initial Phase 1 trial data for EO-3021, an antibody drug conjugate targeting Claudin 18.2, demonstrating a 42.8% confirmed objective response rate in patients with Claudin 18.2-expressing gastric or gastroesophageal junction cancer, along with a differentiated safety profile showing no neutropenia or peripheral neuropathy. The company reported Q2 2024 net loss of $10.5 million, ended the quarter with $110.8 million in cash, and entered clinical supply agreements with Lilly and GSK to evaluate EO-3021 in combination with ramucirumab and dostarlimab respectively by year-end 2024.